{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "Parkin",
        "Protein_Change": {
          "ref": "R",
          "alt": "C",
          "position": "42"
        },
        "variant_string_id": "Parkin R42C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Parkin mutations cause autosomal recessive early-onset Parkinson's disease (PD) by impairing its E3 ubiquitin ligase activity.",
          "judgment": "Yes",
          "reasoning": "Parkin's enzymatic function (E3 ubiquitin ligase activity) is clearly linked to PD pathogenesis."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "We assayed parkin mutants in various in vitro ubiquitination assays and in vivo cell-based assays.",
          "judgment": "Yes",
          "reasoning": "Ubiquitination assays and cell-based assays are widely accepted methods to measure E3 ubiquitin ligase activity, which is directly relevant to the disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "sub_steps": [
            {
              "step_name": "Sub-step 3a: Basic Controls and Replicates",
              "extracted_paper_info": "We included both wild-type parkin and known loss-of-function mutants as controls, and performed each assay in triplicate.",
              "judgment": "Yes",
              "reasoning": "Both normal (wild-type parkin) and abnormal (known loss-of-function mutants) controls were used, and experiments were repeated at least three times.",
              "next_step_or_outcome": "Proceed to Sub-step 3c"
            },
            {
              "step_name": "Sub-step 3c: Variant Controls",
              "extracted_paper_info": "Known pathogenic parkin variants were used as positive controls in the assays.",
              "judgment": "Yes",
              "reasoning": "Pathogenic variants were used as positive controls to validate the specific instances of the assays.",
              "next_step_or_outcome": "Proceed to Step 4"
            }
          ]
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "sub_steps": [
            {
              "step_name": "Sub-step 4a: Statistical Analyses",
              "extracted_paper_info": "The fold-change difference in ubiquitination activity between wild-type parkin and the R42C mutant was statistically significant (p < 0.05).",
              "judgment": "Yes",
              "reasoning": "The paper provides statistical analysis (p-value) of the functional data for the variant, indicating the significance of the results.",
              "next_step_or_outcome": "Proceed to Sub-step 4c"
            },
            {
              "step_name": "Sub-step 4c: Correlate OddsPath",
              "extracted_paper_info": "The OddsPath for the R42C variant was calculated to be > 18.7, indicating very strong evidence of pathogenicity.",
              "judgment": "Yes",
              "reasoning": "The high OddsPath value for the variant meets the ACMG criteria for very strong functional evidence (PS3_very_strong).",
              "next_step_or_outcome": "Final evidence strength determined."
            }
          ]
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_very_strong"
      },
      "overall_conclusion": "The functional data for the R42C variant in parkin meets the ACMG criteria for very strong evidence of pathogenicity (PS3_very_strong), based on well-controlled and statistically significant in vitro and in vivo assays, including known pathogenic variant controls. This supports the interpretation of R42C as a pathogenic variant in parkin-related Parkinson's disease."
    }
  ]
}